Intestinal in Medical Technology

Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced

... Oligopeptides Produced by Transgenic Bacteria on intestinal Injury Due to C. difficile Infection." After ... a bacterial delivery system that will promote intestinal repair and restore the balance of normal ... to be preventative or therapeutic in fighting intestinal inflammation and colon cancer. The GI tract has ...

Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source

... investigators show that Prominin1 marks normal intestinal stem cells and that these cells, when mutated, give rise to intestinal tumors. The finding could also aid in identifying ... intestine is particularly interesting since human intestinal tumors contain Prominin1-expressing cancer stem ...

Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

... down into gliadin which can pass through the intestinal epithelial barrier during times of increased intestinal permeability. The ingestion of gluten causes an ... such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. Celiac disease is a ...

Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain

... (cGMP) plays in alleviating intestinal pain. These studies demonstrate that cGMP inhibits intestinal pain in a preclinical model of intestinal ... into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal ...

'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle

... the diet can help optimize the functioning of the intestinal lining, as well as, the immune system. The role ... in the areas of probiotics and intestinal flora. The Dannon Company is America's founding ... applications for probiotics and the use of intestinal bacteria in human health around the world. The ...

Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

... gluten challenge. Study endpoints included intestinal permeability (IP), measured as lactulose-mannitol ... a dose dependent protection from increase in intestinal permeability as measured by LAMA ratio versus ... enrollment effect resulted in a fall in intestinal permeability from Day 0 to Day 7 across all ...

NPS Reports Successful GATTEX(TM) Extension Study

... chronic disease associated with severe intestinal failure is so difficult to achieve with current ... involved in the regeneration and repair of the intestinal epithelium. NPS is also pursuing development of ... is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and ...

Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease

... Study shows extent of intestinal damage does not explain patients' symptoms ... endoscopy can provide a magnified view of the intestinal damage caused by celiac disease. This new ... reaction in the small intestine, which causes intestinal damage and the subsequent inability to absorb ...

Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study

... of medicine and director of the Center for intestinal Health & Nutrition Support, University of ... new treatment option for our patients with intestinal failure due to massive intestinal loss. We eagerly await the peer review ...

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

... effective but more selective therapy that is less damaging to the normal intestinal bacteria that protect against recurrence of CDI." Additional ... Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological ...

New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus

... coagulans to survive the challenges probiotics face in reaching the intestinal tract where they can do good" and added that "once there, no other strain ... clinical trials using Ganeden BC30 , including trials in immunity, IBS, intestinal gas, Crohn's disease, osteoarthritis, and rheumatoid arthritis. "We will ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... is right for you. Welchol is not for everyone, especially those with intestinal blockage, those with blood triglyceride levels of greater than 500 mg/dL, ... (greater than 300 mg/dL). Tell your doctor if you have stomach or intestinal problems, including gastroparesis (when the stomach takes too long to ...

Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

... which is found in wheat, barley, and rye. It is characterized by small intestinal inflammation and injury. CD is a growing public health concern, affecting ... in long-term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. The only current management of CD is complete ...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

... of commercially-available gabapentin is limited to a narrow region in the intestinal tract and can saturate at normal clinical doses. Once saturation occurs, ... is absorbed by high-capacity nutrient transporters located throughout the intestinal tract," said Ken Cundy, Ph.D., senior vice president, Preclinical ...

Florastor(R) Receives ConsumerLab.com Certification

... organisms, which is essential in the product's promotion of healthy intestinal function through the balance of intestinal flora." Prior to its testing ... infection(1). It is clinically proven to be effective in helping to manage intestinal issues ranging from acute diarrhea to chronic inflammatory conditions ...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile

... candidate REP3123 is shown to stop the production of destructive intestinal toxins caused by Clostridium difficile (C. difficile) bacteria. C. ... use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile ...

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile

... without inhibiting other key organisms that are essential for normal intestinal functioning. C. difficile-associated disease (CDAD), a major cause of ... use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile ...

Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons

... in the highest risk Barrett's population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased rate of disease progression and cancer development, as compared to the control group. In another study ...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

... is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe ...

Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus

... in the highest risk Barrett's population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased the rate of disease progression and cancer development, as compared to the control group. In another study ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... on these attributes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secreting adenomas (watery diarrhea). In addition, octreotide substantially reduces and in many cases can control growth hormone and/or ...

Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin

... difficile . The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence. About ...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe ...

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease

... vedolizumab works by blocking a key inflammatory marker on white blood cells, thereby preventing the migration of these inflammatory cells into the intestinal wall. The two randomized, placebo-controlled, blinded Phase III studies will enroll nearly 2,000 patients in more than 40 countries. Each trial ...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

... on these attributes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secreting adenomas (watery diarrhea). In addition, octreotide substantially reduces and in many cases can normalize growth hormone ...

Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain

... Oral bioavailability was confirmed in multiple species. In contrast to currently marketed opioids, CR845 did not produce inhibition of intestinal transit (ileus) or elicit signs of abuse or addiction liability in animal models. Preclinical studies also indicate that CR845 possesses anti-itch ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... were suppressed between 58 to 64 percent compared to control animals. Pharmacokinetic studies verified the presence of the engineered shRNA in the intestinal mucosa, proving successful delivery of the active hairpin RNA component by the bacterial system. Cequent developed the current tk RNAi candidate on ...

ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer

... are certain risk factors." About Colonoscopy Colonoscopy is a common and very safe procedure that examines the lining of the lower intestinal tract called the colon or large intestine. Colonoscopy means "to look inside the colon." Physicians specially trained in the procedure use a flexible ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

... certolizumab pegol) is an 89-patient Phase IIIb open-label 54-week trial designed to evaluate the efficacy of certolizumab pegol on resolving the intestinal mucosal lesions in patients with active Crohn's disease. CIMZIA was administered subcutaneously at Weeks 0, 2, 4 and then every four weeks. Adverse ...

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

... the intestine. In preclinical testing, linaclotide was shown to decrease visceral pain, increase fluid secretion into the intestine, and accelerate intestinal transit. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories ...

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... business strategy focus on diseases of both lucrative western markets and imperative global health needs." About cholera Vibrio cholerae is an intestinal infection which results in the abrupt loss of large volumes of electrolyte rich watery stools and vomiting, leading to severe and rapidly progressing ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... rash, pruritus, musculoskeletal pain, pyrexia, fatigue (including asthenia and malaise). Adverse drug reactions reported post-marketing include intestinal perforation, interstitial lung disease including pulmonary fibrosis and cutaneous vasculitis. About HUMIRA HUMIRA is the only fully human ...

Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845

... administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. ...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

... mechanism of dendritic cell recruitment and activation. Following oral administration, talactoferrin is transported by the M-cells into the small intestinal Peyer's Patches, where it recruits circulating immature dendritic cells bearing tumor antigens to the GALT and induces their maturation. DC ...

Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia

... should be monitored if TYGACIL is administered with warfarin -- Monotherapy should be used with caution in patients with clinically apparent intestinal perforation -- In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by 25 mg every ...

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

... of the intestine. In preclinical testing linaclotide was shown to decrease visceral pain, increase fluid secretion into the intestine, and accelerate intestinal transit. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 2a trials, linaclotide improved bowel ...

Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains

... is also associate director of international research at the NIH, is an expert on the prevention of gastroenteritis from rotavirus, which infects the intestinal lining. Dr. Glass established a Viral Gastroenteritis Unit at CDC which has conducted epidemiologic and laboratory research and provided leadership ...

Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845

... dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity. About ...

More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL

... should be monitored if TYGACIL is administered with warfarin -- Monotherapy should be used with caution in patients with clinically apparent intestinal perforation -- In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by 25 mg every ...

Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models

... any intent or obligation to update these forward-looking statements. (1) Kim et al. (2005) Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 309. ...